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WAVE 4 – 1 PAGE SUMMARY AUGUST 2021
MOST COMMONLY USED SUBSTANCES IN PAST FOUR WEEKS
Alcohol was the most
commonly used substance
at each wave, although use
declined across waves.
86%
83% 84%
78%
W1 W2 W3 W4
73% 72%
67%
61%
W1 W2 W3 W4
Cannabis remained the
second most commonly
used substance at each
wave. However, reported
use declined in recent
waves despite no change in
perceived availability.
E-cigarette use noticeably
increased at Wave 4. Further,
e-cigarettes had the largest
proportion of participants
(43%) reporting that their use
had increased relative to
before COVID-19 restrictions.
20% 21%
25%
37%
W1 W2 W3 W4
Apart from MDMA and meth/ amphetamine, most
drugs were reported as ‘easy’ or ‘very easy’ to
obtain, with no major changes across waves.
PERCEIVED AVAILABILITY OF SUBSTANCES
Perceived difficulty in
obtaining MDMA
doubled between
Wave 2 and 3 and
remained high at
Wave 4.
22%
(Wave 2)
44%
(Wave 3)
Perceived difficulty in
obtaining
meth/amphetamine
increased at Wave 2,
before declining
sharply at Wave 3 and
stabilising at Wave 4.
56%
(Wave 2)
25%
(Wave 3)
How worried are you that you 
will get COVID-19?
24%
18%
48% 51%
W1 W2 W3 W4
Participants’ concern
about getting COVID-19
varied across waves, but
Waves 3-4 showed that
around half of
participants were ‘not at
all worried’.
COVID-19 CONCERN
MENTAL HEALTH
Mental health treatment
remained common across waves,
with almost half (47%) of
participants reporting accessing
mental health treatment in the
past four weeks at Wave 4.
Ratings of perceived ‘better’
mental health (compared to
before COVID-19 restrictions)
almost doubled between Wave
1 (23%) and Wave 4 (44%).
SAMPLE CHARACTERISTICS
197 participants across 
Australia completed all 
surveys (Waves 1-4).
The median age 
at Wave 4 was 27 
(IQR=23-40).
50% 47%
4%
Half of participants 
identified as female 
(47% as male, 4% as 
non-binary).
The majority of
participants were 
from capital cities. 
79%
Two in five 
participants (42%) 
identified as LGBQ+ 
(58% as heterosexual)
PERCEIVED CHANGES IN 
SUBSTANCE USE
At Wave 4, changes in
perceived use (i.e., increase /
decrease / stable) of most
drugs had mostly remained
stable or decreased compared
to before COVID-19
restrictions.
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What are the aims of the ADAPT Study? 
The Australians' Drug Use: Adapting to
Pandemic Threats (ADAPT) Study is
exploring the short and long-term impacts
of the COVID-19 pandemic on the
experiences of Australians who use illicit
drugs. Findings will be used to ensure drug-
related issues during COVID-19 are better
understood and more accurately
represented, so as to better inform drug
treatment and harm reduction in Australia.
What does the ADAPT Study involve? 
Australians who regularly (i.e. at least once a
month) used illicit drugs in 2019 were
invited to complete an online survey initially
and follow-up surveys in 2-months, 6
months and 12 months. Participants could
opt to complete the Wave 1 survey only.
Wave 4 of the ADAPT Study had a 55%
response rate of the cohort sample.
About this bulletin: 
This bulletin outlines preliminary findings
from the 197 cohort participants who
completed ALL surveys from Waves 1-4.
BACKGROUND
Citation: Baillie, G., Peacock, A., Hammoud, M., Memedovic, S., Barratt, M., Bruno, R., Dietze, P., Ezard, N., Salom, C., Degenhardt,
L., Hughes, C. & Sutherland, R. (2021). Key findings from the ‘Australians’ Drug Use: Adapting to Pandemic Threats (ADAPT)’ Study
Wave 4. ADAPT Bulletin no. 4. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney.
FLOW CHART
247 Consented to Wave 
1 only
702
Wave 1 final sample 
455
Consented to follow-up 
cohort
308 
Completed Wave 2 
(68% of n=452)
3 Ineligible for follow-up
452
Eligible for follow up cohort2 withdrew at Wave 2
138 did not start Wave 2
4 started but did not 
complete Wave 2
268 
Completed Wave 3 
(59% of n=452) 
3 could not be contacted 
at Wave 3
178 did not start Wave 3
1 started but did not 
complete Wave 3
249
Completed Wave 4
(55% of n=452)
197
Completed ALL surveys 1-4
(44% of n=452)
3 could not be contacted 
at Wave 4
189 did not start Wave 4
9 started but did not 
complete Wave 4
WAVE 1- 4 TIMELINE
Wave 1 
29th Apr 2020 –
15th Jun 2020 
(‘Feb 2020’ timepoint 
collected at Wave 1)
Wave 2 
29th Jun 2020 –
22nd Sep 2020
Wave 3 
29th Oct 2020 –
13th Jan 2021
Wave 4 
29th Apr 2021 –
20th Jul 2021
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WAVE 1 CHARACTERISTICS OF COHORT PARTICIPANTS
Invited and completed ALL 
surveys 1-4 (n=197)
Did not complete ALL 
surveys 1-4 (n=255) 
p value for differences 
between groups*
Median age (IQR) 27 (IQR=23-40) 24 (IQR=21-28) .001*
Gender % (n)                                       
Women 
Men 
Non-binary
49.7% (97)
46.7% (91)
3.6% (7)
44.8% (113)
50.0% (126)
5.2% (13)
.812
Sexual orientation % (n)        
Heterosexual 
LGBQ+
57.8% (109)
42.2% (80)
57.7% (143)
42.3% (105)
.671
Completed 
tertiary/university 
qualification % (n)
67.3% (132) 60.2% (153) .214
Area % (n)
Capital city
Regional/rural/remote 
79.1% (155)
20.9% (41)
74.4% (189)
25.6% (65)
.569
Jurisdiction % (n)
NSW
VIC
QLD
WA
SA
ACT
TAS
NT
30.5% (60)
31.0% (61)
15.7% (31)
7.6% (15)
8.1% (16)
2.0% (4)
3.6% (7)
1.5% (3)
31.8% (81)
25.1% (64)
22.0% (56)
7.8% (20)
5.1% (13)
3.9% (10)
3.5% (9)
0.8% (2)
.418
Frequency of illicit drug 
use in 2019 % (n) 
Daily
≥ weekly < daily 
> Monthly < weekly 
Monthly
28.9% (57)
45.2% (89)
13.7% (27)
12.2% (24)
29.0% (74)
40.8% (104)
18.8% (48)
11.4% (29)
.509
W1 Drug of choice % (n)
Cannabis
MDMA
Methamphetamine
Alcohol
LSD
39.3% (77)
10.7% (21)
8.7% (17)
8.2% (16)
7.7% (15)
40.2% (102)
15.0% (38)
7.9% (20)
8.7% (22)
8.7% (22)
.265
The below table presents a comparison of those who completed ALL surveys (i.e. Wave 1-4) and
those who did not among the cohort follow up sample. These two groups were mostly similar with
the exception that the former group were significantly older. It is also worth noting that a substantial
proportion of the sample did not identify as heterosexual. Both these factors should be considered in
all interpretation of findings. (Note that apart from p values presented in the table below, no further
statistical analyses have been undertaken and all further bulletin results are descriptive only.)
IQR: Interquartile range. *p value of <0.05 indicates that there is a significant difference between the two groups
LGBQ+: Lesbian, gay, bisexual, queer or other sexual orientation.
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DRUG USE
Cannabis remained the most common drug
of choice at Wave 4 (39%), although this was
a slight decrease from Wave 3 (44%) and
Wave 2 (43%). Approximately one-in-ten
participants reported alcohol (10%), cocaine
(9%), MDMA (9%) and LSD (9%) as their drug
of choice at Wave 4, which is comparable to
previous waves. At Wave 4, 20% of
participants reported that their drug of
choice had changed from Wave 1 (vs 15% at
Wave 3, 13% at Wave 2).
0%
20%
40%
60%
80%
100%
Wave 1 Wave 2 Wave 3 Wave 4
Figure 1. Drug of choice
13% reported injecting any drug in the
past four weeks, which was stable from
previous waves (13%, 12%, 13% at
Waves 1-3 respectively).
70% reported that they had used drugs
alone in the past four weeks; a slight
decrease from Wave 3 (79%) and Wave
2 (73%) (data not collected at Wave 1).
DRUG USE BEHAVIOURS 
At Wave 4, 5% of participants reported
attending a virtual night club/dance
party since their last survey (vs 10% at
Wave 3) (data not collected at Waves 1-
2).
For those attending a virtual
nightclub/dance party at Wave 4, the
largest proportions reported using
alcohol (80%), MDMA (60%), cocaine
(50%) and/or ketamine (30%).
Figure 2. How worried are you that you will get 
COVID-19?
24%
18%
48% 51%
52%
51%
43% 37%
18%
25%
8%
9%
5%
41%
2%
Wave 1 (n=190) Wave 2 (n=192) Wave 3 (n=192) Wave 4 (n=189)
Not at all Slightly Moderately Very Extremely
COVID-19 EXPERIENCE
By Wave 4, 82% of participants had been
tested for COVID-19, with <1% testing
positive. On average, these participants
had been tested a median of 2 times
(max=21).
Wave 2 saw a spike in participants
reporting that they were ‘very’ worried
about getting COVID-19 (see Figure 2).
These numbers substantially reduced in
subsequent waves, with around half
reporting that they were ‘not at all’
worried at Waves 3-4.
Note: Data labels for ‘Extremely’ not presented in figure to assist visual 
interpretation. Values for Wave 1-4 are 1%, 2%, 0% and 5% respectively 
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Figure 3. Substance use in the past four weeks 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Feb 2020 (i.e. pre-COVID-19 restrictions) Wave 1 (past four weeks)
Wave 2 (past four weeks) Wave 3 (past four weeks)
Wave 4 (past four weeks)
Notes: *Options added at Wave 2 survey. Data for OAT (opioid agonist therapy) medication and ‘other synthetic drugs’ not
presented due to < 5% reporting use at each wave. Non-prescribed use is reported for pharmaceutical medicines. ‘Feb 2020’
data was collected at Wave 1 and is not a separate timepoint. Of the Bulletin 4 sample (n=197), there were <10 missing cases
for each drug and wave depicted in Figure 3.
Alcohol (88%, 86%, 83%, 84%, 78%), cannabis (73%, 73%, 72%, 66%, 61%) and tobacco (43%,
52%, 54%, 55%, 51%) were the main substances used in the past four weeks at each time
point (percentages refer to Feb 2020 and Waves 1, 2, 3, 4 respectively) (See Figure 3). At
Wave 4, e-cigarettes (37%) remained the fourth most commonly used substance, however
the percentage reporting past four-week use had increased considerably compared to
previous waves.
Perceived Changes in Substance Use
Figure 4 (overpage) shows perceived changes in substance use in the last four weeks as
compared to before (i.e., since COVID-19 restrictions in March 2020).
At Wave 4, e-cigarettes (43%) had the largest proportion of participants reporting that their
use had increased in the last four weeks as compared to before (i.e., since COVID-19
restrictions in March 2020), overtaking cannabis (33%) and alcohol (28%) for the first time.
MDMA (49%) nitrous oxide (43%) and cocaine (42%) had the largest proportions of
participants reporting decreased use in the last four weeks, as compared to before.
GHB (61%), amyl/alkyl nitrite (55%) and hallucinogenic mushrooms (53%) had the largest
proportions reporting that their use had remained stable.
PERCEIVED CHANGES IN SUBSTANCE USE
MOST COMMONLY USED SUBSTANCES IN THE PAST FOUR WEEKS
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Figure 4. Waves 1 – 4 Perceived changes in past-month drug use compared to before March 2020
Notes: *Response option added at Wave 2 survey. Non-prescribed use is reported for pharmaceutical medicines. Wave 1 survey 
asked about changes in drug use from the beginning of March 2020 compared to before, while Wave 2-4 surveys asked about 
changes in past month drug use as compared to before March 2020.
56%
46%
30% 33%
45%
35% 34% 28% 26% 23% 29%
43% 33%
20% 25% 18% 17% 15% 19% 11%
32%
36%
37% 32%
25%
35% 37%
34% 49%
56%
56%
41% 51%
56% 40% 50% 46% 46% 46% 47%
12% 18%
33% 35% 30% 30% 29% 38%
26% 21%
15% 17% 16% 24%
36% 32% 37% 39% 35% 42%
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Figure 5. Waves 1 – 4 Perceived availability of substances in the past four weeks
49% 45% 39% 43%
21% 26% 28% 20% 26% 16% 15% 18%
29% 30%
16% 24%
37% 48%
43%
45%
42% 31%
43%
44% 33% 48% 44% 42%
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48%
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11% 6% 17% 9%
25%
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36% 22%
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Cocaine MDMA Meth/amphetamine Pharmaceutical opioids
Very easy Easy Difficult Very difficult
Notes: Non-prescribed use is reported for pharmaceutical medicines. Data not presented for substances where <20 
participants answered at each wave.
Figure 5 shows that most drugs were reported as ‘easy’ or ‘very easy’ to obtain across Waves
1-4, with no major changes across waves. However, the perceived difficulty in obtaining
MDMA increased at Waves 3-4. There was also an increase in the percentage of participants
who reported that meth/amphetamine was 'very difficult' to obtain at Wave 2, however this
declined in Waves 3 and 4 (although small numbers mean these figures must be interpreted
with caution).
PERCEIVED AVAILABILITY
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METHODS OF RECEIVING / PURCHASING DRUGS
81%
40%
5% 6% 6%
69%
48%
5% 8% 6%
72%
38%
6%
14%
7%
74%
40%
5%
15%
6%
79%
35%
7%
19%
4%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Receiving in person Receiving by delivery Grew/made own Didn’t obtain drugs Purchasing online
(surface or darknet)Feb 2020 (i.e. pre-
COVID-19 restrictions)
Wave 1 Wave 2 Wave 3 Wave 4
Figure 6. Methods of receiving / purchasing drugs in past four weeks
Notes: ‘Feb 2020’ data was collected at Wave 1 and is not a separate timepoint. Receiving relates to how participants have
collected or come into the possession of drugs. Purchasing/obtaining relates to how participants organised obtaining drugs
(but not actually collecting drugs). Other methods of purchasing/obtaining (apart from online) are not presented in Figure 6.
At Wave 4, there was a small increase in the percentage of participants who received their
drugs in person in the past four weeks (79% vs 74% at Wave 3, 72% at Wave 2, 69% at Wave 1),
almost returning to levels reported pre-COVID-19 restrictions (Feb 2020, 81%).
The proportion of participants who had their illicit drugs delivered to them in the past four
weeks has varied between waves: Feb 2020 (40%), Wave 1 (48%), Wave 2 (38%), Wave 3 (40%),
Wave 4 (35%).
A relatively small proportion of participants reported that they grew/made own drugs at Wave 4
(7%), stable from previous waves (5% at Wave 3, 6% at Wave 2, 5% at Wave 1, 5% in Feb 2020).
The proportion of participants who did not obtain illicit drugs in the past month continued to
increase at Wave 4 (19%, vs 15% at Wave 3, 14% at Wave 2, 8% at Wave 1 and 6% in Feb
2020).
At Wave 4, 4% reported purchasing their drugs online in the past four weeks (using surface
websites or dark-web markets), which is relatively stable from Wave 3 (6%), Wave 2 (7%) and
Wave 1 (6%).
6%
Had accessed drug 
treatment (stable 
from 6% in Wave 3, 
vs 7% in Wave 2, 4% 
in Wave 1)
0.5%
Tried but were unable 
to access drug 
treatment (vs 2% in 
Waves 1-3)
7%
Tried but were unable to 
access services (stable 
from 4% in Wave 3, vs 5%
in Wave 2, 7% in Wave 1)
47%
Had accessed services 
(stable from 46% in 
Wave 3, vs 47% in Wave 
2, 42% in Wave 1)
Drug Treatment
Treatment engagement remained low:
Mental Health Treatment
Accessing mental health services remained 
relatively common:
TREATMENT ACCESS & ENGAGEMENT IN THE PAST FOUR WEEKS
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PERCEIVED CHANGES IN HEALTH RATINGS
Mental Health
23% 26%
34% 44%
24% 21%
26%
22%
53% 53%
40% 34%
Wave 1
(n=190)
Wave 2
(n=192)
Wave 3
(n=192)
Wave 4
(n=189)
Better Stable Worse
27% 26% 31% 34%
36% 38% 34%
34%
37% 36% 35% 32%
Wave 1
(n=187)
Wave 2
(n=193)
Wave 3
(n=189)
Wave 4
(n=193)
Better Stable Worse
Physical Health
Note: ‘Perceived changes’ are based on perceptions of current health as compared to before March 2020 (i.e. before COVID-
19 restrictions).
DRUG-RELATED HARMS
Ratings of perceived 'better’ mental health has increased across waves (44% at Wave 4 vs
23% at Wave 1), while ratings of perceived physical health have remained relatively consistent
across waves. Those reporting that their current health was ‘worse’ than compared to before
March 2020 no longer comprise the highest proportions for either mental or physical health.
26%
10%
3%
26%
11%
3%
19%
9%
2%
15%
9%
2%
0%
20%
40%
60%
80%
100%
Withdrawal Binged Overdose
Wave 1 Wave 2 Wave 3 Wave 4
Note: Binged defined as using drugs for ≥48 hours without sleep.
Withdrawal defined as experience of any of the following symptoms
when stopped using drugs suddenly: difficulty sleeping, depression,
anxiety, aches and pains, cravings, fatigue, hallucinations, nausea, being
hot and cold, goosebumps, runny nose. Overdose defined as symptoms
outside the normal drug experience, which caused concerns for physical
health, and where professional assistance would be helpful.
Experiences of bingeing and
overdose remained relatively
uncommon across waves.
Participants reporting withdrawal
symptoms in the past four weeks
has decreased slightly across
waves (26%, 26%, 19%, 15% at
Waves 1, 2, 3, 4 respectively).
Among participants reporting
withdrawal, the largest
proportion continued to report
withdrawing from cannabis (30%,
32%, 37%, 37% at Waves 1, 2, 3,
4 respectively). The majority of
these withdrawal episodes
continue to be voluntary (67%,
67%, 57%, 74% at Waves 1, 2, 3,
4 respectively).
Figure 7. Drug-related harms & bingeing  
©NDARC, UNSW SYDNEY 2021. This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining
this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning
reproduction and rights should be addressed to adaptstudy@unsw.edu.au.
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• Similar to previous waves, the ADAPT cohort participants who completed the Wave 4
survey comprised mostly young, well-educated capital city dwellers. Being a convenience
sample, findings from the ADAPT study cannot be considered representative of all people
that use drugs. ​It should be noted that the majority of Wave 4 data was collected prior to
the current COVID-19 restrictions (i.e., mid-July 2021 onwards).
• In contrast to previous waves, e-cigarettes (43%) had the largest proportion of participants
reporting that their use had increased in the last four weeks relative to before COVID-19
restrictions, overtaking cannabis (33%) and alcohol (28%) for the first time.
• However, there was considerable diversity in changes in consumption across individuals
and drug types, highlighting the heterogeneity of experiences among people who use
drugs.
• Perceived availability was reported as ‘easy’/’very easy’ for most drugs, however,
the perceived difficulty in obtaining MDMA increased at Waves 3-4. There was an
increase at Wave 2 in the percentage of participants who reported
that meth/amphetamine was 'very difficult' to obtain, however this subsequently declined
in Waves 3 and 4.
• At Wave 4, the percentage of participants reporting that they had received drugs in
person almost returned to levels observed pre-COVID-19 restrictions, reflecting a steady
increase across Waves 1 – 4. The percentage reporting not obtaining illicit drugs in the past
month also continued to increase across waves (19% at Wave 4).
• Experience of bingeing and overdose remained relatively low and consistent across Waves
1 – 4, while withdrawal has declined across waves.
• Wave 4 saw a continued increase in perceived 'better' mental health
ratings (44%), while ratings of perceived 'better' physical health have remained relatively
consistent across waves.
• Email adaptstudy@unsw.edu.au
• Check out our website at 
www.adaptstudy.org.au
• Follow @NDARCNews or #ADAPTStudy on 
Twitter
• Follow ADAPT Study on Facebook
• The participants who contributed their valuable time to share their experiences.
• The Australian Injecting & Illicit Drug Users League (AIVL) for their support and advice in developing
the project.
• All those who gave advice and shared information about the project.
• The National Drug and Alcohol Research Centre and the Australian Government Department of
Health for funding support.
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